文献速递乳腺癌放疗放疗物理与技术

无创图像引导乳腺近距离放疗加速部分乳腺照射的2期试验

Phase 2 Trial of Accelerated Partial Breast Irradiation (APBI) Using Noninvasive Image Guided Breast Brachytherapy (NIBB).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-07-25

这项前瞻性2期研究评估了无创图像引导乳腺近距离放疗(NIBB)实施加速部分乳腺照射(APBI)的初步结果。

要点

  • NIBB APBI耐受良好,无≥3级晚期毒性,5年美容优良率100%。
  • 5年间侧乳腺肿瘤复发豁免率93.3%,总生存率93.7%。
  • 乳房间距>7 cm与毛细血管扩张相关(P < .01)。

核心结论

  • NIBB实施APBI耐受良好,显著晚期毒性发生率低,美容效果良好。
  • 需要在更大队列中继续评估NIBB APBI技术。

研究设计与样本

  • 处方剂量34 Gy分10次,每日或每日两次,使用Ir-192高剂量率源经专用施源器照射。
  • 主要终点为2年和5年评估的晚期毒性和美容效果。

主要发现

  • 中位年龄68岁(范围50-92岁),平均肿瘤大小1.1 cm(范围0.3-3.0 cm)。
  • 任何时间点均未观察到≥3级晚期毒性,2年和5年2级毒性分别为5%和10%。
  • 毛细血管扩张1级和2级发生率分别为27.5%和5%,乳房间距>7 cm与毛细血管扩张相关(P < .01)。
  • 2年和5年美容优良率分别为95%和100%;中位随访68个月,5年 actuarial 间侧乳腺肿瘤复发豁免率为93.3%(±4.8%),总生存率为93.7%(±4.4%)。

关键数值与推荐

  • NIBB APBI处方剂量为34 Gy分10次。
  • 晚期毒性采用NCI CTCAE v3.0评估,美容效果采用NRG/RTOG量表评估。

临床怎么用

  • NIBB APBI可作为早期乳腺癌患者的一种无创、高精度APBI选择。
  • 乳房间距>7 cm的患者接受NIBB APBI时需关注毛细血管扩张风险。

局限性

  • 中位随访68个月,长期结局仍需进一步观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Noninvasive image guided breast brachytherapy (NIBB) is a novel approach to delivery of accelerated partial breast irradiation (APBI) that may hold advantages over established techniques. NIBB is not invasive but maintains a high level of precision by using breast immobilization via breast compression and image guidance; it therefore does not require large planning tumor volume margins. We present the primary outcomes of this prospective phase 2 study (BrUOG Br-251). METHODS AND MATERIALS: Eligible patients with early-stage breast cancer underwent NIBB APBI using a dose 34 Gy in 10 fractions delivered daily or twice a day. Treatment was delivered using an Ir-192 high-dose-rate source via specialized applicators. Two orthogonal treatment axes were used for each fraction. The primary endpoints were late toxicity and cosmesis assessed at 2 and 5 years. Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. Cosmesis was assessed using the NRG/Radiation Therapy Oncology Group scale. Ipsilateral breast tumor recurrence was defined as any recurrence or new primary in the treated breast. RESULTS: Forty patients underwent protocol treatment. Median patient age was 68 years (50-92 years). Mean tumor size was 1.1 cm (0.3-3.0 cm). Among the cohort, 62.5% had invasive carcinoma and 37.5% had ductal carcinoma in situ. Thirty-nine percent elected to receive hormone therapy. No grade ≥3 late toxicities were observed at any time point. Grade 2 toxicity was 5% and 10% at 2 and 5 years, respectively. Telangiectasia grade 1 and 2 occurred in 27.5% and 5%, respectively. Breast separation of >7 cm was associated with telangiectasia (P < .01). The rate of good to excellent cosmetic outcome was 95% at 2 years and 100% at 5 years. With a median follow-up of 68 months, the actuarial 5-year freedom from ipsilateral breast tumor recurrence was 93.3% (±4.8%), and overall survival was 93.7% (±4.4%). CONCLUSIONS: NIBB to deliver APBI is well tolerated with a low incidence of significant late toxicity and has favorable cosmetic outcomes. Continued evaluation of the NIBB APBI technique in a larger cohort is warranted.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hepel JT, Leonard KL, Sha S, et al. Phase 2 Trial of Accelerated Partial Breast Irradiation (APBI) Using Noninvasive Image Guided Breast Brachytherapy (NIBB). Int J Radiat Oncol Biol Phys. 2020. PMID: 32721422. doi:10.1016/j.ijrobp.2020.07.2312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。